Fein: Stay the Course on Biosimilars
...
Top Story
Featured Stories
Fein: Stay the Course on Biosimilars
While Peter Bach and Mark Trusheim argue for throwing in the proverbial towel on biosimilars, Adam Fein suggests the two… Read more
Article Considers International Pricing Index for More than Part B Drugs
While the Trump administration is exploring an international pricing index for Medicare Part B drugs, the U.S. appears… Read more
Should the U.S. Government Get More Involved in Drug Prices?
The U.S. government should look to other economically developed countries with a heavier hand in drug pricing in order… Read more
Latest Stories
Fein: Stay the Course on Biosimilars
While Peter Bach and Mark Trusheim argue for throwing in the proverbial towel on biosimilars, Adam Fein suggests the two are surrendering too early."This strategy [price regulation] may save some money in the short run, but it risks destroying a market that is finally beginning to fulfill its […]
Article Considers International Pricing Index for More than Part B Drugs
While the Trump administration is exploring an international pricing index for Medicare Part B drugs, the U.S. appears to pay more for Part D drugs than other countries, the authors of a recent Health Affairs blog post write."While international drug price comparisons are challenging, two […]
Should the U.S. Government Get More Involved in Drug Prices?
The U.S. government should look to other economically developed countries with a heavier hand in drug pricing in order to better wrangle drug prices, the authors of a recent article published on The Conversation write.More government involvement in drug prices, however, has gained "little favor" […]
FDA’s Woodcock Outlines Problem Areas of Medical Innovation
Janet Woodcock, director of the Food and Drug Administration's (FDA) Center for Drug Evaluation and Research, had a blunt message for a crowd of roughly 150 researchers on the state of medical innovation in the U.S., according to a Los Angeles Times report: "It's not working, and it won't work in […]
Warren Adds Drug Pricing to Campaign
Democratic Sen. Elizabeth Warren added a health care plan to her presidential campaign, as well as policies to wrangle drug prices, hours before the Sept. 12 presidential debate, InsideHealthPolicy reports.According to the report, the proposed bill, the Affordable Drug Manufacturing Act, would […]
Article Looks at How Drugs Are Priced
A recent report by Investor's Business Daily spotlights how pharmaceutical companies put a price tag on their drugs.According to the report, drugmakers in the first half of this year rolled out price increases on 3,400 drugs by an average of 10.5 percent, five times the rate of […]
States Taking Action on Drug Prices
Thirty-three states so far this year have passed a record 51 laws to address rising drug prices and affordability, Kaiser Health News reports.According to the report, 28 states passed 45 laws in 2018."Legislative activity in this area is escalating," Trish Riley, National Academy for State […]
Report: Novo Nordisk Slashing U.S. Insulin Prices
Danish drugmaker Novo Nordisk announced its plans to cut the prices of insulin in the U.S. amid rising criticism over the treatment's high prices, Reuters reports.According to the report, the drugmaker will offer a generic version of Novolog, an insulin drug used by roughly one million patients […]
Germany as a Model for Drug Pricing Solutions?
With American policymakers working to find solutions to rising drug prices, Germany's model could hold some clues, the author of a recent article published on Harvard Business School's Working Knowledge writes.Germany since 2011 has required pharmaceutical companies justify high price tags for […]
Makary Discusses Health Care, New Book on Relentless Health Value Podcast
A new Relentless Health Value podcast features Dr. Martin Makary to discuss his new book, "The Price We Pay: What Broke American Health Care — and How to Fix It."Makary, a surgeon, is both a New York Times best-selling author and Johns Hopkins health policy expert."I could not recommend this […]
